aTyr Pharma (NASDAQ:LIFE) Announces Quarterly Earnings Results, Beats Estimates By $0.01 EPS

aTyr Pharma (NASDAQ:LIFE) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.23) earnings per share for the quarter, beating the consensus estimate of ($0.24) by $0.01, Yahoo Finance reports. The company had revenue of $0.24 million for the quarter, compared to analysts’ expectations of $0.11 million.

aTyr Pharma Trading Up 0.6 %

Shares of LIFE stock traded up $0.01 on Friday, hitting $1.61. The stock had a trading volume of 258,118 shares, compared to its average volume of 498,541. The company has a debt-to-equity ratio of 0.02, a current ratio of 6.27 and a quick ratio of 6.27. The firm has a market capitalization of $109.38 million, a P/E ratio of -1.68 and a beta of 1.27. aTyr Pharma has a 1 year low of $1.08 and a 1 year high of $2.70. The company’s 50 day moving average price is $1.78 and its 200-day moving average price is $1.55.

Analysts Set New Price Targets

LIFE has been the topic of a number of research analyst reports. Royal Bank of Canada reduced their target price on aTyr Pharma from $19.00 to $16.00 and set an “outperform” rating on the stock in a research report on Friday, March 15th. HC Wainwright restated a “buy” rating and issued a $35.00 target price on shares of aTyr Pharma in a research report on Friday. One equities research analyst has rated the stock with a sell rating, one has given a hold rating and three have issued a buy rating to the company. Based on data from MarketBeat, the stock presently has a consensus rating of “Hold” and a consensus price target of $23.67.

About aTyr Pharma

aTyr Pharma, Inc, a biotherapeutics company, engages in the discovery and development of medicines based on novel immunological pathways in the United States. Its lead therapeutic candidate is efzofitimod, a selective modulator of NRP2 that is in Phase III clinical trial for pulmonary sarcoidosis; and in Phase 1b/2a clinical trial for treatment of other interstitial lung diseases (ILDs), such as chronic hypersensitivity pneumonitis and connective tissue disease related ILD.